NCT03387566View on ClinicalTrials.gov

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

February 1, 2020

Study Completion Date

March 23, 2020

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

HB002.1M

HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Huabo Biopharm Co., Ltd.

INDUSTRY